Allogeneic bone marrow transplantation is the only established curative treatment for patients with CML. However, relapse remains a significant problem. The 4-year probWe studied the outcome of BMT in 38 consecutive CML patients in CP1 who received transplants depleted of ability of hematologic relapse for patients transplanted with an unmanipulated graft in CP1 varies from 9 to 21%.
lymphocytes using counterflow centrifugation. In all patients the conditioning regimen was intensified by the It increases to 25-80% for patients transplanted in more advanced phases. 1, 3, 5 T cell depletion reduces the incidence addition of anthracyclines. Donors were HLA, MLCidentical siblings. Six patients (16%) died within 6 and severity of GVHD but also increases the risk of relapse. [6] [7] [8] [9] The probability of relapse after transplantation months. All 37 patients with a follow-up of more than 0.5 months engrafted and only one (3%) suffered from for CML-CP1 with lymphocyte-depleted grafts is 40-65%. [2] [3] [4] [9] [10] [11] If hematologic and cytogenetic relapses are acute GVHD у grade 3. Chronic GVHD was evaluable in 33 patients and was extensive in six (18%). The procombined, the probability of relapse is even higher. 12 However, the Ph chromosome may appear only transiently and jected 5-year probabilities of hematologic, cytogenetic and molecular relapse were 30% (95% confidence interis not neccessarily followed by hematological relapse.
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The clinical relevance of a small number of persisting cells val (CI), 10-49%), 35% (95% CI, 14-56%), and 34% (95% CI, 13-55%), respectively. The projected 5-year expressing the BCR-ABL mRNA has been discussed by several authors. [17] [18] [19] [20] It has been speculated whether the probability of survival was 68% (95% CI, 50-86%). Projected at 5 years, probablities of leukemia-free surcomplete disappearance of the BCR-ABL gene rearrangement was necessary for cure of the disease. 18, [20] [21] [22] However, vival (LFS) in hematologic, cytogenetic and molecular remission were 55% (95% CI, 37-73%), 51% (95% CI, using PCR with nested primers, a relationship was observed between PCR positivity and relapse. 23, 24 Quantitative PCR 32-69%), and 51% (95% CI, 32-70%), respectively. All patients with relapse but one who relapsed in blastic in consecutive samples showed that the number of residual tumor cells had important prognostic value. 21, [25] [26] [27] [28] phase were treated with retransplantation (n = 1) or with the infusion of lymphocytes (n = 6). Six patients For CML patients who relapse, treatment options are limited. In patients with cytogenetic or hematological relapse, regained second hematologic remission and five entered second cytogenetic and molecular remission. Including ␣-interferon significantly improved the 2-year probability of survival but long-term survival did not differ from that these patients, the probability of survival in first or second hematologic remission at the end of follow-up in patients who were not treated with ␣-interferon.
29
Retransplantation is associated with a high treatmentwas 68% (95% CI, 50-86%). The probabilities of survival in first or second cytogenetic and molecular related morbidity and mortality. Following a second transplant for CML 2-year probabilities (95% confidence interremission at the end of follow-up were both 61% (95% CI, 42-80%). We advocate revaluation of T cell val (CI)) of treatment-related mortality, relapse and leukemia-free survival were 35% (95% CI, 20-53%), 43% (95% depletion of donor marrow for patients with CML-CP1, especially for those at high risk of developing CI, 27-62%), and 37% (95% CI, 23-53%), respectively.
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Retransplantation may become more successful since trans-GVHD. Keywords: T cell-depleted BMT; CML-CP1; LFS; plant-related mortality can be reduced by less intensive conditioning regimens, such as high-dose busulphan survival in first or second complete remission alone. 31 Recently, several authors have reported on the treatment of relapse after bone marrow transplantation with the infusion of leukocytes from the original marrow donor. [32] [33] [34] Complete remission was induced in 54 patients (73%) with relapsed CML. 35 In the present analysis we report on the outcome of trans- grafts depleted of lymphocytes using counterflow centrifug-ation. All patients received a conditioning regimen which (International Medical, Zutphen, The Netherlands) have been placed eccentrically in a rotor (type Mark-1; Dijkstra was intensified by the addition of anthracyclines. In all patients with a relapse, except one who relapsed into blastic Vereenigde, Amsterdam, The Netherlands) that has been installed in a modification (Curame-3000) of the Varifugephase, we attempted to induce second remission with retransplantation (n = 1) or with the infusion of lympho-RF centrifuge (Heraeus Separationstechnic, Ostenrode, Germany). The particles in the separation chamber are subcytes from the original marrow donor (n = 6). Using this form of immunotherapy, we observed high probabilities of jected to two opposing forces: the centrifugal force depending upon the rotor speed and the centripetal force LFS and of survival in first or second remission.
caused by the continuous fluid stream pumped into the chamber with a direction towards the rotor axis. At equilibrium the cells are positioned according to their size with Materials and methods the larger cells in the more centrifugal position and the smaller cells in the more centripetal direction. By increasPatients, donors and methods ing the centripetal force and/or decreasing the centrifugal Between July 1986 and August 1995, 61 consecutive force this equilibrium shifts towards the outlet of the patients were transplanted for CML-CP1. Fifteen patients chamber and the smaller cells are the first to leave the were excluded from analysis because they received marrow chamber. The rotor outlets are monitored for cell number from non-HLA, MLC-identical family donors (n = 7) or and size using a computerized cell scatter-controlled matched unrelated donors (n = 8). Another eight patients device. The cells are collected in several rotor speed fracwere excluded since indication for transplantation was Ph tions. In each fraction the number of nucleated cells is meachromosome and BCR/ABL breakpoint negative CML (n sured by using a cell counter (Coulter Counter; Coulter = 1) or conditioning for BMT was performed without the Corporation, Hialeah, FL, USA). After binding to CD3-addition of anthracyclines (n = 7 [36] [37] [38] Four patients were conbody weight/day. As soon as CsA could be taken orally, it ditioned without TBI. They received idarubicin to a total was given in a dose of 6 mg/kg body weight/day to 12 dose of 42 mg/m 2 by continuous i.v. infusion on days −12 weeks after BMT, followed by a gradual tapering off and and −11, busulphan 4 mg/kg/body weight (days −8 to −5 discontinuation after 16 weeks post-grafting. inclusive) and cyclophosphamide 60 mg/kg/body weight on days −3 and −2. Bone marrow was infused on day 0.
Management of patients
All patients were managed in single rooms with filtered air Donor marrow under positive pressure throughout the transplantation period inside the hospital, and all received oral selective gut Donor marrow was depleted of lymphocytes by density gradient centrifugation followed by counterflow centrifugdecontamination, as well as co-trimoxazole for Pneumocystis carinii prophylaxis and oral acyclovir for prophylaxis ation as described before. 39, 40 In summary: bone marrow is filtered through a nylon filter with a pore size of 70 m.
of herpes infection. After removal of plasma and fat, a mononuclear cell fraction with a density Ͻ1.073 g/ml is isolated in gradients of GVHD Percoll (Percoll, Uppsala, Sweden). Then the low density mononuclear fraction is pumped into the separation
The clinical manifestations of acute GVHD were graded 1 to 4 according to the criteria described by Glucksberg et chamber which is placed eccentrically in a centrifugation rotor. The separation capacity of the original singleal. 41 Chronic GVHD was classified as limited or extensive as described by Shulman et al. 42 If GVHD occurred р3 chamber rotor (Beckman JE-6; Beckman, Palo Alto, CA, USA) has been enhanced by the development of a multimonths after retransplantation or р3 months after the infusion of lymphocytes it was defined as acute. If the chamber counterflow centrifugation system with four separation chambers reducing the total time of the elutriation patients had GVHD beyond 3 months, it was defined as chronic. procedure to about 3 h. The transparant chambers Bone marrow samples survived in second hematologic, cytogenetic or molecular remission if they regained hematologic, cytogenetic or molAs part of an ongoing study on chimerism, bone marrow ecular remission, respectively, and remained in that samples were taken before BMT, 0.5 and 1 year after transremission until the end of follow-up. For these patients folplantation and annually thereafter. From 1991 onwards, low-up was calculated from T cell-depleted BMT onwards. bone marrow samples were analyzed prospectively for the Take failure was defined as primary (leukocytes always presence of BCR/ABL breakpoint molecules. PCR analysis Ͻ1.0 × 10 9 /l) or as secondary (leukocytes у1.0 × 10 9 /l on of samples taken before 1991 was done retrospectively in 3 or more consecutive days with disappearance of leukoliquid nitrogen stored bone marrow. If cytogenetic analysis cytes in further follow-up). for the Ph chromosome and/or PCR for the BCR/ABL breakpoint was positive, bone marrow samples were taken Follow-up and analyzed at shorter intervals.
Follow-up was until death or 1 August 1996. For surviving patients, follow-up was at least 12 months.
Cytogenetic analysis
For demonstration of the Ph chromosome, bone marrow
Treatment of relapse cells were prepared directly and/or cultured for 24 h in RPMI 1640 medium (Gibco, Paisley, UK) without mitoBefore the era of lymphocyte infusions for the treatment of gens and processed for GTG banding. 43 As a standard, 32 relapse, one patient had been retransplanted directly with metaphases were analyzed. unmanipulated marrow from the original donor. Conditioning for second BMT consisted of busulphan 16 mg/kg and cyclophosphamide (200 mg/kg). Six patients with a relapse PCR analysis were given lymphocytes from the original marrow donor Two series of PCR were performed as described before. 44 as described before. 35, 44 In summary: RNA was isolated from bone marrow cells in a modification of the method of Chomczynski and Sacchi. 45 
Statistics
Primers for the synthesis of cDNA (A21) and for the two series of PCR were derived from the Sequence, Fisher's exact test was used for comparison of two pro-EMBL/Genebank accession No. M30828 (Heidelberg, portions. Calculations were made using the Statistica Germany). Primers B11 and A21 were used in the first 30-Release 4.1 programme (Apple Computer, Cupertino, CA, cycle series and the internal primers B12 and A22 in the USA). P values Ͻ0.05 were considered significant. The second 35-cycle PCR. The quality of each RNA sample probabilities of relapse, survival and LFS were calculated was assessed in a reverse transcriptase reaction followed using the Kaplan-Meier method. Differences in probby PCR on ␤ 2 -microglobulin RNA. Strict precautions were abilities were calculated using the log-rank test and Wiltaken to avoid contaminations. In each PCR, both positive coxon's test. Calculations were made using the SAS proand negative controls were used. PCR products were anagramme (SAS Institute, Cary, NC, USA). P values Ͻ0.05 lyzed by hybridization after Southern blotting using a 32 Pwere considered significant. The Kaplan-Meier method labeled c-ABL probe recognizing the 5′ part of exon 2 of was also used for the calculation of the probability of surthe c-ABL gene. With this PCR, we were able to demonvival in first or second remission at the end of follow-up. strate one K562 cell among 10 5 normal cells. For this calculation, patients who relapsed and attained second remission after retransplantation or after the infusion of lymphocytes were not scored for relapse. ProbDefinitions ability of survival in first or second remission was calcuHematologic relapse was defined as the reappearance of lated from T cell-depleted BMT onwards and was given clinical features and laboratory findings characteristic for only for the endpoint of follow-up. Probability of survival CML. Cytogenetic relapse was the recurrence of metain second remission was given separately for survival in phases with the Ph chromosome. A molecular relapse was second hematologic, cytogenetic and molecular remission. defined as a positive PCR at two or more consecutive points of time after BMT.
If PCR for BCR/ABL was negative and the patient had Results no cytogenetic or hematologic relapse, he was in molecular remission. The patient was in cytogenetic remission if the
Interval from diagnosis to transplantation bone marrow showed no Ph chromosome-positive metaphases and the patient had no hematologic relapse. HematoInterval from diagnosis to transplantation varied from 3 to 62 (median 10) months. Twenty-nine patients (76%) were logic remission was defined as the disappearance of signs or symptoms of CML and normalization of blood counts transplanted р12 months after diagnosis of CML. Four of 29 patients (14%) who were transplanted р1 year after and bone marrow cellularity in the absence of antileukemic therapy.
diagnosis relapsed hematologically compared to three of nine (33%) transplanted beyond 1 year (P Ͼ0.05). A com-LFS was defined as survival in first hematologic remission. If LFS refers to survival in first cytogenetic or parable difference was observed for cytogenetic and molecular relapse, respectively (data not shown). first molecular remission this is stated in the text. Patients Take failure death are given in Table 2 . Only one patient died from relapse at 50 months after T cell-depleted BMT. He All 37 patients with a follow-up of more than 0.5 months relapsed at 48 months in blastic phase and was treated engrafted. Two patients (5%) suffered from secondary take symptomatically only. One patient died in molecular failure at 2 and 3 months, respectively. Both were retransremission from overwhelming pneumococcal sepsis at 69 planted with an unmanipulated graft after conditioning with months after the first BMT and 27 months after retransplantotal lymphoid irradiation given in two fractions of 2 Gy tation for relapse. She was not immunized with pneumococon each of 3 consecutive days to a total dose of 12 Gy.
cal vaccine after (re)transplantation. Cause of death was One of these patients died from GVHD at 3 months after Ebstein-Barr virus-associated secondary lymphoma in one retransplantation. The other remained in molecular patient. She died 17 months after T cell-depleted transplanremission at 40 months after the first BMT and 38 months tation. after retransplantation.
Relapse GVHD

Acute GVHD occurred after T cell-depleted BMT and
Hematologic relapse was observed in seven patients at 12-48 (median 24) months after T cell-depleted BMT. In three before retransplantation or the infusion of lymphocytes in 20 of 37 engrafted patients (54%). Twelve patients (32%) patients hematologic relapse occurred at 4-12 (median 6) months after cytogenetic and at 6-23 (median 12) months had acute GVHD grade 1, seven (19%) grade 2 and one patient (3%) suffered from grade 3 acute GVHD.
after molecular relapse. The probability of hematological relapse was 30% (95% CI, 10-49%) and is given in Chronic GVHD before retransplantation or before lymphocyte infusion occurred in 16 of 33 patients (48%) with Figure 1 . Eight patients had a cytogenetic relapse at 6-48 (median a follow-up of Ͼ3 months. GVHD was limited in 10 (30%) and extensive in six patients (18%).
24) months after BMT. In one of these patients cytogenetic relapse was preceded by molecular relapse which occurred The incidence but not the severity of acute GVHD in the nine patients after retransplantation (n = 3) or after the 19 months earlier. The probability of cytogenetic relapse was 35% (95% CI, 14-56%) and is shown in Figure 1 . infusion of lymphocytes (n = 6) was significantly higher than that observed in these patients after T cell-depleted Thirteen patients had positive PCR for the BCR/ABL breakpoint at 6-48 (median 24) months after transplan-BMT ( Table 1 ). The incidence of extensive chronic GVHD was significantly higher after retransplantation (n = 1) or tation. In five patients PCR was only positive at one timepoint after BMT. At that time, none of these five recipients after the infusion of lymphocytes (n = 6) in the seven patients who were evaluable for chronic GVHD after T had cytogenetic or hematologic relapse and PCR was negative in two to five consecutive analyses in later follow-up. cell-depleted BMT and after retransplantation or after lymphocyte infusion and this is shown in Table 1 .
As given in the definitions, these patients were not considered as having a molecular relapse. Molecular relapse occurred in eight patients at 6-48 (median 18) months after Mortality transplantation. One patient had a molecular relapse without evidence of cytogenetic or hematologic relapse at the Ten of 38 patients (26%) died at 0.5-69 (median 6) months after lymphocyte-depleted BMT. The principal causes of time of molecular relapse. Nineteen and 23 months later he relapsed cytogenetically and hematologically, respectively. death and the interval between T cell-depleted BMT and Table 1 The incidence and severity of acute and chronic GVHD after T cell-depleted BMT and after retransplantation or the infusion of lymphocytes
No. (%) of patients with GVHD P value
After T After retransplantation cell-depleted BMT or lymphocyte infusion
No. of patients = 9
Acute GVHD none 6 (67) this curve is not given.
Survival
Twenty-eight of 38 patients (74%) were alive at 12-120 (median 51) months after BMT. Of these, seven were alive after retransplantation for secondary take failure (n = 1) or after the infusion of lymphocytes (n = 6). The probability of survival is given in Figure 2 and was 68% (95% CI, 50-86%).
Probability of leukemia-free survival
At 12-120 (median 45) months, 23 of 38 patients (61%) were alive and in first hematologic remission. Probability of LFS was 55% (95% CI, 37-73%) and is given in Figure  3 . Twenty-two of 38 patients (58%) were alive and in first cytogenetic remission at 12-120 (median 43) months after T cell-depleted BMT. The probability of LFS in first cyto- genetic remission was 51% (95% CI, 32-69%) and is given 
Probability of LFS in molecular remission was 51% (95%
The difference between the probability of leukemia-free survival was not significant. CI, 32-70%). Since the curve for LFS in molecular remission was almost identical to that of LFS in cytogenetic relapse after transplantation for CML-CP1 with T celldepleted grafts varied from 48% at 3 years after BMT to remission this curve is not shown.
65% at 8 years post-transplant. [2] [3] [4] 11 Several factors may have contributed to this relatively low incidence of hematoProbability of survival in first or second remission logic relapse observed in our population. Firstly, when counterflow centrifugation is used for depletion of lymphoSeven patients were treated for relapse with retransplantation (n = 1) or with the infusion of lymphocytes from the cytes, it retains the relatively large lymphocytes in the graft. This lymphocyte population contains most of the large original marrow donor (n = 6). The patient who was given a second transplant with an unmanipulated graft for hemagranular lymphocytes which belong to the MHC nonrestricted cytotoxic cells (natural killer (NK) cells) having the tologic relapse died in molecular remission from overwhelming pneumococcal sepsis at 27 months after retranscapability to inhibit the growth of fresh clonogenic CML cells. 49 This suggests that NK cells are precursors or effecplantation. Five patients were given lymphocytes for hematologic relapse and all regained hematologic remission tors of graft-versus-leukemia reaction. The phenotype of MHC nonrestricted cytotoxic cells is predominantly CD3
− and all but one entered second cytogenetic and molecular remission. One patient received lymphocytes for cytoand CD16 + while a small population bears CD3 and CD16.
50 These cells will also be eliminated if depletion genetic relapse only. At 12-120 (median 51) months after T cell-depleted BMT, 28 of 38 patients (74%) were alive techniques with monoclonal antibodies are used for lymphocyte depletion. Secondly, the addition of anthracyclines and in first or second hematologic remission. The probability of survival in first or second hematologic remission to the conditioning regimen may have decreased the probability of relapse as described earlier. [36] [37] [38] However, this at the end of follow-up and calculated from T cell-depleted BMT onwards was 68% (95% CI, 50-86%). Twenty-six of appeared not to be due to the additional elimination of leukemic cells by anthracyclines but more to the relatively 38 patients (68%) were alive and in cytogenetic remission at 12-120 (median 51) months after lymphocyte-depleted higher incidence of GVHD as reported by Bä r et al. 51 They observed a lower incidence of mixed erythrocyte chimer-BMT. The probability of survival in first or second cytogenetic remission at the end of follow-up from T cellism, a higher incidence of acute GVHD у grade 1 and a trend to a lower relapse rate in patients conditioned with depleted BMT onwards was 61% (95% CI, 42-80%). This probability will increase further if the two patients who still the addition of anthracyclines. The addition of anthracyclines to the conditioning regimen may have resulted primhad Ph chromosome-positive metaphases after lymphocyte infusion enter a second cytogenetic remission. The probarily in an additional elimination of immunocompetent autologous T lymphocytes tipping the immunological balability of survival in first or second molecular remission at the end of follow-up and calculated from T cell-depleted ance towards the low number of T lymphocytes given within the graft. Thirdly, 29 of 38 patients (76%) were BMT onwards was identical to that of survival in first or second cytogenetic remission.
transplanted within 1 year after diagnosis of CML and this may be another explanation for the relatively low probability of relapse. Patients transplanted beyond 1 year after diagnosis of CML tended to have a higher relapse incidence Discussion than patients transplanted within 1 year after diagnosis, although these differences were not significant. [2] [3] [4] In the present analysis, acute GVHD у grade 2 occurred in eight of 37 patients (22%). This contrasts favorably with The probabilities of cytogenetic and molecular relapse did not differ significantly from that of hematologic relapse. results from the study for the EBMT of Ringdén et al. 46 They observed acute GVHD у grade 2 in 305 of 780
In all but one of the eight patients cytogenetic relapse heralded or occurred simultaneously with hematologic relapse patients (39%) after first transplantation for CML-CP1 with grafts from HLA-identical siblings. In 22% of cases, grafts and molecular relapse preceded or coincided with cytogenetic relapse. Our policy is to treat patients only with the were T cell-depleted. In the same study, day 100 mortality for CML-CP1 patients was 17%. In contrast, only three of infusion of donor lymphocytes if cytogenetic relapse has been observed at two or more consecutive occasions with 38 patients (8%) in the present analysis had died at day 100. The relatively low incidence of acute GVHD у grade an increasing percentage of Ph chromosome-positive metaphases. Patients with a molecular relapse only are not 2 in our patients is reflected in the relatively low day 100 mortality. Seven out of 10 patients died beyond day 100. treated. LFS after transplantation for CML-CP1 with T cellNowadays, three of these patients might have been saved by adoptive immunotherapy, 47 an earlier diagnosis of depleted and HLA-identical sibling grafts varied from 37% at 2 years to 21% at 8 years after BMT. 4, 7, 52 After transplanimpending relapse 28 or by pneumococcal prophylaxis.
48
The incidence of acute and the severity of chronic tation for CML-CP1 with unmanipulated grafts from HLAidentical siblings, LFS varied from 44% at 8 years to 68% GVHD after retransplantation with an unmanipulated graft or after the infusion of lymphocytes was higher than that at 2 years post-transplant. 3, 4, 52 In contrast to Goldman et al 2 others concluded that T cell-depletion significantly reduced observed in these patients after T cell-depleted BMT. This observation shows that for each patient individually the LFS. 3, 4 In the present analysis LFS projected at 5 years after BMT was 55% and is comparable with LFS obtained occurrence and severity of GVHD depends on the number of lymphocytes infused.
in recipients of unmanipulated marrow. Patients who relapse from CML can be treated with The projected 5-year probability of hematologic relapse in our patients was 30%. The probability of hematologic retransplantation or preferably with the infusion of lympho- 
